Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer-Reference-Cited by-同舟云学术

Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer

Published:2020-07-29 Issue:9 Volume:17 Page:3553-3566
ISSN:1543-8384
Container-title:Molecular Pharmaceutics
language:en
Short-container-title:Mol. Pharmaceutics

Author:

Dekempeneer Yana¹²^ORCID,Caveliers Vicky²³,Ooms Maarten¹,Maertens Dominic¹,Gysemans Mireille¹,Lahoutte Tony²³,Xavier Catarina²,Lecocq Quentin⁴,Maes Ken⁵,Covens Peter²,Miller Brian W.⁶,Bruchertseifer Frank⁷,Morgenstern Alfred⁷,Cardinaels Thomas¹⁸^ORCID,D’Huyvetter Matthias²

Affiliation:

1. Institute for Nuclear Materials Science, Belgian Nuclear Research Center (SCK CEN), 2400 Mol, Belgium

2. In Vivo Cellular and Molecular Imaging Laboratory, Vrije Universiteit Brussel (VUB), 1090 Brussels, Belgium

3. Department of Nuclear Medicine, UZ Brussel, 1090 Brussels, Belgium

4. Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium

5. Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel (VUB), 1050 Brussels, Belgium

6. Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado 80045, United States

7. Directorate for Nuclear Safety and Security, European Commission−Joint Research Centre, Karlsruhe 76344, Germany

8. Department of Chemistry, KU Leuven, Heverlee, 3000 Leuven, Belgium

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.molpharmaceut.0c00580

Reference57 articles.

1. Untangling the ErbB signalling network

2. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

3. Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials

4. 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

5. Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

2. Advances in bismuth utilization for biomedical applications – From a bibliometric perspective;Coordination Chemistry Reviews;2024-10

3. Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-06

4. Qualitative and quantitative imaging of alpha‐emitting radiopharmaceuticals;iRADIOLOGY;2024-06-25

5. Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands;Pharmaceuticals;2024-02-16